Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 179

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 179
---
 customers, suppliers, employees and
other constituencies. We believe that consolidating the leadership of the Company under Mr. Rosén is the appropriate leadership
structure for our Company and that any risks inherent in that structure are balanced by the oversight of our other independent directors
on our Board. However, no single leadership model is right for all companies and at all times. The Board recognizes that depending on
the circumstances, other leadership models, such as the appointment of a lead independent director, might be appropriate. Accordingly,
the Board may periodically review its leadership structure. In addition, the Board holds executive sessions in which only independent
directors are present.

| 101 |

Our Board is generally responsible
for the oversight of corporate risk in its review and deliberations relating to our activities. Our principal source of risk falls into
two categories, financial and product commercialization. The audit committee oversees management of financial risks; our Board regularly
reviews information regarding our cash position, liquidity and operations, as well as the risks associated with each. The Board regularly
reviews plans, results and potential risks related to our business. The Board is also expected to oversee risk management as it relates
to our compensation plans, policies and practices for all employees including executives and directors, particularly whether our compensation
programs may create incentives for our employees to take excessive or inappropriate risks which could have a material adverse effect on
the Company.

Director Independence

As required under the Nasdaq
Marketplace Rules, a majority of the members of a listed company’s board of directors must qualify as “independent,”
as affirmatively determined by the board of directors. Our Board of Directors considered certain relationships between our directors and
us when determining each director’s status as an “independent director” under Rule 5605(a)(2) of the Nasdaq Marketplace
Rules. Based upon such definition and SEC regulations, the Company’s Board of Directors has affirmatively determined that currently
three of its seven directors (Christer Rosén, Marshall Hayward, Ph.D., and Alison D. Silva) are non-independent directors of the
Company and four of its seven directors (Nicholas H. Hemmerly, Julie Kampf, Allison W. Brady, and Holger Weis) are “independent”
directors under the Nasdaq listing standards. Therefore, the Board of Directors has determined that a majority of the members of our Board
of Directors are “independent”.

Committees of the Board of Directors

Audit Committee

We have established an audit
committee (“Audit